Supernus Pharmaceuticals Other Current Assets 2011-2024 | SUPN

Supernus Pharmaceuticals other current assets from 2011 to 2024. Other current assets can be defined as field containing the sum of all current assets that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
Supernus Pharmaceuticals Annual Other Current Assets
(Millions of US $)
2023 $
2022 $
2021 $
2020 $
2019 $
2018 $
2017 $
2016 $
2015 $
2014 $
2013 $
2012 $
2011 $
2010 $
Supernus Pharmaceuticals Quarterly Other Current Assets
(Millions of US $)
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31
2015-09-30
2015-06-30
2015-03-31
2014-12-31
2014-09-30
2014-06-30
2014-03-31
2013-12-31
2013-09-30
2013-06-30
2013-03-31
2012-12-31
2012-09-30
2012-06-30
2012-03-31
2011-12-31
2011-09-30
2011-06-30
2011-03-31
2010-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $1.978B $0.608B
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.350B 6.35
Dr Reddy's Laboratories (RDY) India $11.677B 22.35
BridgeBio Pharma (BBIO) United States $4.392B 0.00
Bausch Health Cos (BHC) Canada $3.009B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.142B 12.88
Taysha Gene Therapies (TSHA) United States $0.447B 31.14
Personalis (PSNL) United States $0.239B 0.00
Assembly Biosciences (ASMB) United States $0.094B 0.00
Sol-Gel Technologies (SLGL) Israel $0.013B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00